Floatz logo

TAMOXIFEN

Progesterone-Receptor Positive Breast Cancer

Jennifer Lee Caswell-JinSmall moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Progesterone-Receptor Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Letrozole
Ruth O'Regan
Phase 2BB
Cyclophosphamide
University of Washington
Phase 2B
FILGRASTIM
University of Washington
Phase 2B
Palbociclib
Abramson Cancer Center at Penn Medicine
Phase 2B
Inno-206
University of Washington
Phase 2B

View all 36 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →